To the best of our knowledge, our study is the first to reveal an oncogenic role for NHE9 and to elucidate the mechanism of CRT resistance in ESCC patients with increased NHE9 expression. This evidence concerns the gene SLC9A9 and esophageal squamous cell carcinoma.